JPRN-UMIN000013704招募中未知
Targeting Complete Response in Younger transplant-eligible Multiple myeloma patients with Bortezomib and Lenalidomide treatment after relapse with autologous stem cell transplantation - CYMBAL study
Division of Hematology, Saitama Medical Center, Jichi Medical University0 个研究点目标入组 41 人开始时间: 2014年4月14日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 41
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with a past history of allergy to the drug described in the protocol 2) Patients daiagnosed plasma cell neoplasm other than symptomatic multiple myeloma 3) Patients who cannnot be expected to live for more than 3 months 4) Patients who have had a complication of active double cancer* within the past 5 years *Excluding basal cell carcinoma of the skin, squamous cell carcinoma, epithelial carcinoma in situ considered to have been cured by topical treatment, or lesions corresponding to intramucosal carcinoma (cervical carcinoma presenting in FIGO stage I) 5) HBs antigen, HCV antibody or HIV antibody positive patients 6) Patients with grade 2 or severer peripheral neuropathy or peripherl neurogenic pain (CTCAE v4.0) 7) Patients who have or suspected of having a serious active infection 8) Patients with serious mental disorders 9) Patients with serious pulmonary dysfunction 10) Patients with a clinical picture of pneumonia (interstitial pneumonia) or fibroid lung or an abnormal bilateral interstitial abnormality (e.g. a shadow of ground-glass opacity) on CT scan regardless of the presence or absence of symptoms (these patients should be enrolled after consultation with a respiratory specialist or radiologist) 11) Patients who have serious cardiac dysfunction or present with ECG or a chest diagnostic image that indicates treatment 12) Patients who are complicated by poorly controlled diabetes mellitus 13) Patients who are receiving hemodialysis 14) Patients who have serious liver dysfunction 15)Women who are or may be pregnant or are nursing 16) Other patients who are, in the opinion of the caring investigator, unfit for enrolloment in this study
研究者
相似试验
Unknown
1 期
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft FunctionKidney FailureNCT03791476University of Wisconsin, Madison20
进行中（未招募）
1 期
Simplified basic immunisation after transplantation of stem cellsPatients undergoing stem cell transplantation loose their protection from basic vaccinations done during childhood and need to be immunised again to be protected from diphteria, tetanus, polio and haemophilus influenza. Improved protection against pertussis will also be studied.EUCTR2014-005077-36-SEÖrebro Läns Landsting50
进行中（未招募）
1 期
A randomised controlled trial of regulatory immune cells (Tregs) to allow reduction of immunosuppression following renal transplantation.EUCTR2017-001421-41-GBniversity of Oxford136
进行中（未招募）
1 期
Allogeneic stem cell transplantation for children, adolescents and young adults with acute myeloid leukemiaEUCTR2007-004517-34-CZHannover Clinical Trial Center GmbH153
进行中（未招募）
1 期
Stem cell transplantation for young people with severe blood cancerRelapsed or refractory Acute Myeloid Leukemia (AML)MedDRA version: 20.0 Level: LLT Classification code 10000886 Term: Acute myeloid leukemia System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10067859 Term: Allogenic stem cell transplantation System Organ Class: 100000004865EUCTR2007-004517-34-DEHannover Medical School153